Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ABBV - Harpoon Therapeutics: T-Cell Engager Platform For Immune-Related Disease

ABBV - Harpoon Therapeutics: T-Cell Engager Platform For Immune-Related Disease

AbbVie Inc.
  • Harpoon Therapeutics is a platform immunotherapy company using its TriTAC technology to develop more stable bispecifics to treat cancer.
  • The company has several catalysts for its pipeline of four clinical assets this year that can validate the TriTAC platform.
  • Ultimately, Harpoon has the platform and business model to rapidly scale partnerships and their pipeline pending data releases on their drug candidates this year.

For further details see:

Harpoon Therapeutics: T-Cell Engager Platform For Immune-Related Disease
Stock Information
Company Name: AbbVie Inc.
Stock Symbol: ABBV
Market: NYSE
Website: abbvieinvestor.com
Menu
ABBV ABBV Quote ABBV Short ABBV News ABBV Articles ABBV Message Board
Get ABBV Alerts

News, Short Squeeze, Breakout and More Instantly...